Transcenta Holding Receives FDA Clearance to Proceed with Global Phase III Trial of Osemitamab

Transcenta Holding Receives FDA Clearance to Proceed with Global Phase III Trial of Osemitamab

By, Admin 5 October 2023

Transcenta Holding has received FDA clearance to proceed with the TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as a first-line treatment for patients with HER2-negative, CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal (G/GEJ) adenocarcinoma.

Osemitamab (TST001) is a second-generation humanised antibody designed to target CLDN18.2 with improved binding affinity and enhanced antibody-dependant cellular cytotoxicity (ADCC). It has demonstrated anti-tumour activity in preclinical models with a wide range of CLDN18.2 expression levels.

The goal of this Phase III trial is to evaluate the efficacy and safety of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as a first-line treatment for HER2-negative G/GEJ adenocarcinoma. This combination therapy approach, specifically targeting CLDN18.2, has the potential to redefine the treatment approach for G/GEJ cancer.

Phase II clinical trials were conducted in both the U.S. and China to support the global Phase III trial application and the FDA End-of-Phase 2 (EOP2) meeting. These Phase II trials included various dosing cohorts of Osemitamab (TST001) in combination with chemotherapy or Nivolumab and chemotherapy to determine the optimal dose for the upcoming Phase III trial.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!